- Home
- GOF vs NVAX Comparison
GOF vs NVAX Comparison
Compare GOF & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- NVAX
- Stock Information
- Founded
- GOF 2006
- NVAX 1987
- Country
- GOF United States
- NVAX United States
- Employees
- GOF N/A
- NVAX N/A
- Industry
- GOF Finance/Investors Services
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOF Finance
- NVAX Health Care
- Exchange
- GOF Nasdaq
- NVAX Nasdaq
- Market Cap
- GOF 2.4B
- NVAX 1.3B
- IPO Year
- GOF N/A
- NVAX 1995
- Fundamental
- Price
- GOF $14.95
- NVAX $6.80
- Analyst Decision
- GOF
- NVAX Buy
- Analyst Count
- GOF 0
- NVAX 5
- Target Price
- GOF N/A
- NVAX $16.60
- AVG Volume (30 Days)
- GOF 789.2K
- NVAX 5.2M
- Earning Date
- GOF 01-01-0001
- NVAX 08-07-2025
- Dividend Yield
- GOF 15.42%
- NVAX N/A
- EPS Growth
- GOF N/A
- NVAX N/A
- EPS
- GOF N/A
- NVAX 2.97
- Revenue
- GOF N/A
- NVAX $1,254,962,000.00
- Revenue This Year
- GOF N/A
- NVAX $56.85
- Revenue Next Year
- GOF N/A
- NVAX N/A
- P/E Ratio
- GOF N/A
- NVAX $2.29
- Revenue Growth
- GOF N/A
- NVAX 25.92
- 52 Week Low
- GOF $10.96
- NVAX $5.01
- 52 Week High
- GOF $16.76
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- GOF 59.79
- NVAX 51.68
- Support Level
- GOF $14.76
- NVAX $6.23
- Resistance Level
- GOF $14.95
- NVAX $6.90
- Average True Range (ATR)
- GOF 0.12
- NVAX 0.30
- MACD
- GOF 0.02
- NVAX 0.01
- Stochastic Oscillator
- GOF 91.42
- NVAX 67.00
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.